Report Ocean | Market Research Report | Industry Analysis | Market Trends | Forecasting
 SALES@REPORTOCEAN.COM
 +1 888 212 3539 (US - TOLL FREE)    +91 999 711 2116 (REST OF WORLD)

CAR T Cell Therapy Market

Market Introduction

Chimeric Antigen Receptor (CAR) T-cell therapy is type of cancer treatment or an immunotherapy that direct T cells to destroy and recognize cancer, it is an innovation since the development of chemotherapy. Chimeric antigen receptors (CARs) cells are developed in laboratory and falls under the category of genetically engineered cells which are collected by doctors and modified in a laboratory. These engineered cells are infused into a body of the patient, which help to detect and fight cancer. Since the early 1990s, CAR T-cell therapy has been under development. Life science researchers are steadily working on novel ways to modify Chimeric Antigen Receptor (CAR) T cell therapy and human immune system. According to Cancer Research Institute, in 2015, there were 27 clinical trials on cancer immunotherapies which increased to 35 trials in 2016.

CAR-T cell products deal with solid tumors that will offer a larger market potential in future years. CAR-T therapy identify antigens with strong efficacy and beyond liquid cancers, other than CD19.

Drivers and restrain factor of the market

Increasing demand of CAR-T therapies are proliferating the growth of CAR-T companies. Drivers supporting the market growth are demand for new treatment methods, increasing healthcare expenditure, rising life science research investment and growing prevalence of blood cancer and others are some important factors driving global CAR T-cells market in forecast period.  Additionally, increasing investment in the CAR-T cell research, approvals for CAR-T cell therapies by various regulatory organizations, high number of IPOs in the industry, and various others are the opportunities which market can leverage for growth.

Considering the driver part of the market, specially growing prevalence of blood cancer.

As per American Cancer Society, blood cancer survival rate remains approx. 60% in five year of span period. In those shares of cancers, blood cancer accounts for highest type of detected cancer i.e. 92% of the cases, in the age group of 0-25 years. Adding some more instances, such as in the U.S., 10.2% of the total new cancer are accounted as blood cancer i.e., approx. 7% of the world. Moreover, with treatment procedures that are adopted presently, blood cancer relapsing treatment rate will remain 80% after five years of treatment. Resultantly, major research organizations and healthcare facilities are focusing on novel treatment procedures to treat blood cancer. In the area of blood cancer treatment, CAR-T cells therapy holds a promising future.

 

Major players in the market

The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global CAR T cell therapy market. Key players are Novartis International AG, Kite Pharma Inc., Juno Therapeutics, Cellectis, Bellicum Pharmaceuticals Inc. and Celgene Corporation among others.

 

Novartis International AG, Kite Pharma Inc., Juno Therapeutics are some of the major players in the CAR T- cell therapy market. Novartis launched CTL019, an anti-CD19 T-cell therapy. The product named as tisagenlecleucel-T is used to treat acute lymphoblastic leukaemia (ALL) in paediatric patients. As per the trial study by American Society of Haematology, CTL019 has complete remission rate of 82%. Similarly, Kite Pharmaceuticals Ltd. Launched axicabtageneciloleucel (Kte-CD19) to treat large B-cell lymphoma. Other market players such as Bellicum Pharmaceuticals, Celgene Corporation, Juno Therapeutics Inc. Pfizer (Cellectics Ltd.) and others are also continuously working on new product developments and research.

Recent key developments in the market

In February 2018, Celularity raised $250 million to support the development of placental-derived products, including for T-cells.

In April 2018,Allogene Therapeutics, a London-based CAR-T start-up collaborated with Pfizer in an asset contribution deal and announced a $300 million Series A round.

Leading region and fastest growing region 

Market Introduction

Chimeric Antigen Receptor (CAR) T-cell therapy is type of cancer treatment or an immunotherapy that direct T cells to destroy and recognize cancer, it is an innovation since the development of chemotherapy. Chimeric antigen receptors (CARs) cells are developed in laboratory and falls under the category of genetically engineered cells which are collected by doctors and modified in a laboratory. These engineered cells are infused into a body of the patient, which help to detect and fight cancer. Since the early 1990s, CAR T-cell therapy has been under development. Life science researchers are steadily working on novel ways to modify Chimeric Antigen Receptor (CAR) T cell therapy and human immune system. According to Cancer Research Institute, in 2015, there were 27 clinical trials on cancer immunotherapies which increased to 35 trials in 2016.

CAR-T cell products deal with solid tumors that will offer a larger market potential in future years. CAR-T therapy identify antigens with strong efficacy and beyond liquid cancers, other than CD19.

Drivers and restrain factor of the market

Increasing demand of CAR-T therapies are proliferating the growth of CAR-T companies. Drivers supporting the market growth are demand for new treatment methods, increasing healthcare expenditure, rising life science research investment and growing prevalence of blood cancer and others are some important factors driving global CAR T-cells market in forecast period.  Additionally, increasing investment in the CAR-T cell research, approvals for CAR-T cell therapies by various regulatory organizations, high number of IPOs in the industry, and various others are the opportunities which market can leverage for growth.

Considering the driver part of the market, specially growing prevalence of blood cancer.

As per American Cancer Society, blood cancer survival rate remains approx. 60% in five year of span period. In those shares of cancers, blood cancer accounts for highest type of detected cancer i.e. 92% of the cases, in the age group of 0-25 years. Adding some more instances, such as in the U.S., 10.2% of the total new cancer are accounted as blood cancer i.e., approx. 7% of the world. Moreover, with treatment procedures that are adopted presently, blood cancer relapsing treatment rate will remain 80% after five years of treatment. Resultantly, major research organizations and healthcare facilities are focusing on novel treatment procedures to treat blood cancer. In the area of blood cancer treatment, CAR-T cells therapy holds a promising future.

 

Major players in the market

The report covers a detailed competitive outlook that includes the market share and company profiles of key players operating in the global CAR T cell therapy market. Key players are Novartis International AG, Kite Pharma Inc., Juno Therapeutics, Cellectis, Bellicum Pharmaceuticals Inc. and Celgene Corporation among others.

 

Novartis International AG, Kite Pharma Inc., Juno Therapeutics are some of the major players in the CAR T- cell therapy market. Novartis launched CTL019, an anti-CD19 T-cell therapy. The product named as tisagenlecleucel-T is used to treat acute lymphoblastic leukaemia (ALL) in paediatric patients. As per the trial study by American Society of Haematology, CTL019 has complete remission rate of 82%. Similarly, Kite Pharmaceuticals Ltd. Launched axicabtageneciloleucel (Kte-CD19) to treat large B-cell lymphoma. Other market players such as Bellicum Pharmaceuticals, Celgene Corporation, Juno Therapeutics Inc. Pfizer (Cellectics Ltd.) and others are also continuously working on new product developments and research.

Recent key developments in the market

In February 2018, Celularity raised $250 million to support the development of placental-derived products, including for T-cells.

In April 2018,Allogene Therapeutics, a London-based CAR-T start-up collaborated with Pfizer in an asset contribution deal and announced a $300 million Series A round.

Leading region and fastest growing region 

Regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America and Middle East and Africa.Geographically, North America dominate the global CAR T Cell Therapy Market, owing to increasing ongoing regulatory approvals and R&D programs. On the other hand, Asia Pacific is expected to be the fastest growing market in CAR T cell therapy market during the forecast period.

Market segment

In this report, the market analysis is done by segmenting the market to limit the scope. Thus, global CAR-T Cell Therapy market is segmented on the basis of targeted antigen and treatment. The targeted antigen segment includes HER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO and EGFRvIII; while on the other hand, treatment segment consists of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), multiple myeloma, acute myeloid leukemia (AML), breast cancer, pancreatic cancer, neuroblastoma (NB), colon cancer and hepatocellular carcinoma (HCC).

Market segment

In this report, the market analysis is done by segmenting the market to limit the scope. Thus, global CAR-T Cell Therapy market is segmented on the basis of targeted antigen and treatment. The targeted antigen segment includes HER1, HER2, CD19, CD20, CD22, CD30, CD33, GD2, MESO and EGFRvIII; while on the other hand, treatment segment consists of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), multiple myeloma, acute myeloid leukemia (AML), breast cancer, pancreatic cancer, neuroblastoma (NB), colon cancer and hepatocellular carcinoma (HCC).

Scroll to Top